Eloxx Pharmaceuticals, Inc. SEC filings ELOX
Eloxx Pharmaceuticals, Inc. has 1,000 filings in SEC EDGAR's recent list, going back to Dec 23, 2008. Its latest annual report, Form 10-K, was filed on Mar 17, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 22, 2026 (officer or director change, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Sep 18, 2026 | — |
| EFFECT | Filing | Jun 8, 2026 | — |
| CERT | Filing | Jun 8, 2026 | — |
| 8-A12B | Filing | Jun 1, 2026 | — |
| DRS | Filing | Mar 20, 2026 | — |
| NT 10-Q | Filing | Aug 14, 2025 | Jun 30, 2025 |
| NT 10-Q | Filing | May 15, 2025 | Mar 31, 2025 |
| NT 10-K | Filing | Apr 1, 2025 | Dec 31, 2024 |
| SEC STAFF ACTION | Filing | Feb 21, 2025 | — |
| NT 10-Q | Filing | Nov 19, 2024 | Sep 30, 2024 |
| NT 10-Q | Filing | Aug 14, 2024 | Jun 30, 2024 |
| NT 10-Q | Filing | May 15, 2024 | Mar 31, 2024 |
| NT 10-K | Form nt 10-k | Apr 1, 2024 | Dec 31, 2023 |
| 25-NSE | Delisting notice | Mar 21, 2024 | — |
| CT ORDER | Filing | Apr 24, 2023 | — |
| EFFECT | Filing | Aug 30, 2021 | — |
| CORRESP | Letter to the SEC | Aug 26, 2021 | — |
| UPLOAD | Letter from the SEC | Aug 26, 2021 | — |
| EFFECT | Filing | Nov 26, 2018 | — |
| CORRESP | Letter to the SEC | Nov 21, 2018 | — |
| UPLOAD | Letter from the SEC | Nov 20, 2018 | — |
| CERT | Filing | Apr 25, 2018 | — |
| 8-A12B | Filing | Apr 24, 2018 | — |
| EFFECT | Filing | Apr 20, 2018 | — |
| CORRESP | Letter to the SEC | Apr 20, 2018 | — |
| CT ORDER | Filing | Apr 20, 2018 | — |
| NT 10-Q/A | Filing | Mar 8, 2018 | Mar 31, 2017 |
| NT 10-K/A | Filing | Mar 8, 2018 | Jun 30, 2017 |
| SC 14F1 | Filing | Dec 7, 2017 | — |
| NT 10-K | Filing | Sep 28, 2017 | Jun 30, 2017 |
| NT 10-Q | Filing | May 15, 2017 | Mar 31, 2017 |
| RW | Filing | Oct 31, 2016 | — |
| NT 10-K | Filing | Sep 28, 2016 | Jun 30, 2016 |
| NT 10-K | Filing | Sep 28, 2015 | Jun 30, 2015 |
| CT ORDER | Filing | Jun 15, 2015 | — |
| D | Filing | May 15, 2015 | — |
| CT ORDER | Filing | Oct 15, 2014 | — |
| EFFECT | Filing | Dec 11, 2013 | — |
| CORRESP | Letter to the SEC | Dec 9, 2013 | — |
| CORRESP | Letter to the SEC | Dec 6, 2013 | — |
| CORRESP | Letter to the SEC | Nov 27, 2013 | — |
| UPLOAD | Letter from the SEC | Oct 25, 2013 | — |
| EFFECT | Filing | Sep 30, 2013 | — |
| 25-NSE | Delisting notice | Nov 23, 2012 | — |
| CT ORDER | Filing | Jul 2, 2012 | — |
| CT ORDER | Filing | Apr 12, 2012 | — |
| EFFECT | Filing | Nov 9, 2010 | — |
| EFFECT | Filing | Jun 23, 2010 | — |
| CORRESP | Letter to the SEC | Jun 22, 2010 | — |
| CORRESP | Letter to the SEC | Jun 17, 2010 | — |
| UPLOAD | Letter from the SEC | Jun 9, 2010 | — |
| CORRESP | Letter to the SEC | Jun 2, 2010 | — |
| UPLOAD | Letter from the SEC | May 13, 2010 | — |
| D | Filing | Apr 9, 2010 | — |
| CT ORDER | Filing | Mar 10, 2009 | — |
| CT ORDER | Filing | Mar 6, 2009 | — |
Showing 56 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ELOX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Arlington, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1035354
- Former names
- Sevion Therapeutics, Inc. (until Dec 22, 2017); SENESCO TECHNOLOGIES INC (until Sep 29, 2014); NAVA LEISURE USA INC (until May 24, 1999)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.